# Claris Ventures

> Claris Ventures is a VC fund in Torino backing Biotechnology and Health Care. See 17 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Torino, Italy
- Total investments: 17
- Last investment: Dec 2025
- Lead investor: 59%
- Last fund: Jul 2021
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/clarisventures/
- X (Twitter): https://twitter.com/ClarisVentures
- Website: http://www.clarisventures.com/

Claris Ventures is a venture capital firm focused on early-stage investments in high potential biopharma companies arisen from the Italian R&D ecosystem

## Contacts

5 contacts available for Claris Ventures. Shizune tracks 3 team members at Claris Ventures. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/claris-ventures?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $2.1M–$11M |
| Series A | $6.1M–$23M |
| Series B | $7.4M–$21M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 6 | 35% |
| Health Care | 3 | 18% |
| Life Science | 2 | 12% |
| Therapeutics | 2 | 12% |
| Pharmaceutical | 2 | 12% |

10 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 5 | 29% |
| Series A | 3 | 18% |
| Series B | 2 | 12% |
| Venture - Series Unknown | 1 | 6% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Italy | 8 | 47% |
| United Kingdom | 1 | 6% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Ciro Spedaliere | Partner | 3 | https://shizune.co/investors/profile/ciro-spedaliere |
| Barbara Castellano | Investment committee member | 7 | https://shizune.co/investors/profile/laura-iris-ferro |
| Lola Buono | Senior Associate | 1 | https://shizune.co/investors/profile/lola-buono |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Lever Bio | Lever Bio's vision is to be at the forefront of unlocking groundbreaking advancements in biotech, particularly in the field of immuno-oncology. By fostering strategic collaborations with leading researchers, prestigious universities, and innovative research centers, Lever Bio aims to accelerate the development of cutting-edge therapies andtechnologies | $5.9M | Seed | Dec 22, 2025 |  |
| Lever Bio | Lever Bio's vision is to be at the forefront of unlocking groundbreaking advancements in biotech, particularly in the field of immuno-oncology. By fostering strategic collaborations with leading researchers, prestigious universities, and innovative research centers, Lever Bio aims to accelerate the development of cutting-edge therapies andtechnologies | $4.5M | Seed | May 28, 2025 |  |
| Iama Therapeutics | At IAMA Therapeutics, we are constantly pushing the boundaries of neuroscience drug discovery to develop new medicines and make a difference in the lives of children suffering from brain disorders and their families. Our purpose is to provide a therapeutic solution to children suffering from neurological conditions and provide their families withthe support they need. | $17.1M | Venture - Series Unknown | Apr 16, 2025 |  |
| NeoPhore | NeoPhore is a provider of novel small molecule therapies intended to treat cancer through stimulation of the immune system.The company's small molecule therapies target genetic mechanisms in order to create neoantigen which is known to stimulate the immune system and potentially be a weak spot in a tumor cell's defense mechanisms,enabling cancer patients to get treated and achieve improved clinical outcomes. | $12.2M | Series B | Feb 01, 2024 |  |
| Resalis Therapeutics | Resalis Therapeutics sviluppa un farmaco in grado di inibire un micro-RNA per il trattamento di alcune malattie metaboliche | $10.9M | Series A | Jan 04, 2024 |  |
| ALKemist Bio | ALKemist Bio provides cell treatment to cancer patients. | $7.6M | Seed | Dec 21, 2023 |  |
| ALKemist Bio | ALKemist Bio provides cell treatment to cancer patients. | $7.6M | Seed | Dec 21, 2023 |  |
| Repron Therapeutics | Repron Therapeutics provides treatments for solid tumor cases where radical excision is not possible and metastasis or recurrence is extremely likely. | $2.1M | Seed | Jun 06, 2023 |  |
| Repron Therapeutics | Repron Therapeutics provides treatments for solid tumor cases where radical excision is not possible and metastasis or recurrence is extremely likely. | $2.1M | Seed | Jun 06, 2023 |  |
| Resalis Therapeutics | Resalis Therapeutics sviluppa un farmaco in grado di inibire un micro-RNA per il trattamento di alcune malattie metaboliche | $10.6M | Seed | Feb 22, 2023 |  |

10 of 17 investments shown.

## Co-investors
- [Club degli Investitori](https://shizune.co/investors/profile/club-degli-investitori) — VC Fund, 7 deals together
- [3B Future Health Fund](https://shizune.co/investors/profile/helsinn-investment-fund) — VC Fund, 5 deals together
- [Italian Angels for Growth](https://shizune.co/investors/profile/italian-angels-for-growth) — VC Fund, 5 deals together
- [2invest](https://shizune.co/investors/profile/2invest-f4d3) — VC Fund, 3 deals together
- [Astellas Venture Management](https://shizune.co/investors/profile/astellas-venture-management) — VC Fund, 3 deals together
- [CDP Venture Capital](https://shizune.co/investors/profile/cdp-venture-capital) — VC Fund, 3 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar country
- [CDP Venture Capital](https://shizune.co/investors/profile/cdp-venture-capital) — VC Fund
- [Club degli Investitori](https://shizune.co/investors/profile/club-degli-investitori) — VC Fund
- [Primo Capital](https://shizune.co/investors/profile/barcamper-ventures) — VC Fund

## Featured in investor lists
- [All VC Funds in Italy](https://shizune.co/investors/vc-funds-italy)
- [All Investors in Italy](https://shizune.co/investors/investors-italy)
- [Health Care VC Funds in Italy](https://shizune.co/investors/health-care-vc-funds-italy)
- [Biotechnology Investors in Italy](https://shizune.co/investors/biotechnology-investors-italy)
- [Biotechnology VC Funds in Italy](https://shizune.co/investors/biotechnology-vc-funds-italy)
- [Biotech Investors in Italy](https://shizune.co/investors/biotech-investors-italy)

## FAQ

### What does Claris Ventures invest in?

Claris Ventures invests primarily in Biotechnology, Health Care and Life Science startups, most often at Seed and Series A stage. Most of the 17 investments tracked by Shizune back companies in Italy. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Claris Ventures's check size?

Claris Ventures typically joins rounds of $2.1M–$11M at Seed, $6.1M–$23M at Series A and $7.4M–$21M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Claris Ventures participates in.

### How do I contact Claris Ventures?

Public channels for Claris Ventures include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Claris Ventures?

The team at Claris Ventures includes Ciro Spedaliere (Partner), Barbara Castellano (Investment committee member) and Lola Buono (Senior Associate). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co